The most recent phase 3 COG study, AALL0631, added the FLT3 inhibitor lestaurtinib to post-induction chemotherapy for infants with KMT2A-rearranged ALL, with no improvement to overall outcome (17). The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.